CM Nolan, L Roll, SV Goldberg and AM Elarth
Tuberculosis Control Program, Seattle-King County Department of Public Health, Washington 98104, USA.

This study was designed to determine whether an integrated screening program could be implemented that identified persons with latent tuberculosis infection among jail inmates and produced a high rate of completion of isoniazid preventive therapy (IPT) in those persons after their discharge from short-term detention, by means of community-based directly observed preventive therapy (DOPT). From June 1, 1992 through December 31, 1994 inmates in the King County Jail who were from populations at high risk of tuberculosis were screened by means of the tuberculin skin test and those with latent tuberculosis infection were offered IPT. Among 262 inmates receiving IPT upon release from jail, 105 (40%) could not be located after release. Among another 105 enrolled on DOPT, 63 (60%) completed therapy. Among 52 who chose self- supervised isoniazid therapy after release, 15 (29%) completed therapy (chi-square = 13.50, p = 0.0002). Among persons with latent tuberculosis infection detected during screening at a county jail, a postrelease DOPT program resulted in a high rate of immediate loss to follow-up and a low rate of completion of therapy. Based on these results, we suggest that funds for TB control, if limited, should not be diverted to jail-based screening and postrelease DOPT.

This article has been cited by other articles:

				A. Kwara, J. S. Herold, J. T. Machan, and E. J. Carter Factors Associated With Failure To Complete Isoniazid Treatment for Latent Tuberculosis Infection in Rhode Island Chest, April 1, 2008; 133(4): 862 - 868. [Abstract] [Full Text] [PDF]

				M. C. White, J. P. Tulsky, E. Menendez, S. Arai, J. Goldenson, and L. M. Kawamura Improving tuberculosis therapy completion after jail: translation of research to practice Health Educ. Res., April 1, 2005; 20(2): 163 - 174. [Abstract] [Full Text] [PDF]

				L. B. Reichman, A. Lardizabal, and C. H. Hayden Considering the Role of Four Months of Rifampin in the Treatment of Latent Tuberculosis Infection Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 832 - 835. [Full Text] [PDF]

				C. R. Horsburgh Jr. Priorities for the Treatment of Latent Tuberculosis Infection in the United States N. Engl. J. Med., May 13, 2004; 350(20): 2060 - 2067. [Abstract] [Full Text] [PDF]

				C. H. Hayden, B. T. Mangura, I. Channer, G. E. Patterson, M. R. Passannante, and L. B. Reichman Tuberculin Testing and Treatment of Latent TB Infection Among Long term Jail Inmates Journal of Correctional Health Care, January 1, 2004; 11(1): 99 - 117. [Abstract] [PDF]

				M. F. Hovell, C. L. Sipan, E. J. Blumberg, C. R. Hofstetter, D. Slymen, L. Friedman, K. Moser, N. J. Kelley, and A. Y. Vera Increasing Latino Adolescents' Adherence to Treatment for Latent Tuberculosis Infection: A Controlled Trial Am J Public Health, November 1, 2003; 93(11): 1871 - 1877. [Abstract] [Full Text] [PDF]

				N. W. Schluger Challenges of Treating Latent Tuberculosis Infection Chest, June 1, 2002; 121(6): 1733 - 1735. [Full Text] [PDF]

				T. Bandyopadhyay, H. Murray, and M. L. Metersky Cost-effectiveness of Tuberculosis Prophylaxis After Release From Short-term Correctional Facilities* Chest, June 1, 2002; 121(6): 1771 - 1775. [Abstract] [Full Text] [PDF]

				M. C. White, J. P. Tulsky, J. Goldenson, C. J. Portillo, M. Kawamura, and E. Menendez Randomized Controlled Trial of Interventions to Improve Follow-up for Latent Tuberculosis Infection After Release From Jail Arch Intern Med, May 13, 2002; 162(9): 1044 - 1050. [Abstract] [Full Text] [PDF]

				T. M. Hammett, C. Roberts, and S. Kennedy Health-Related Issues in Prisoner Reentry Crime Delinquency, July 1, 2001; 47(3): 390 - 409. [Abstract] [PDF]

				R. Laniado-Laborin Tuberculosis in Correctional Facilities : A Nightmare Without End in Sight Chest, March 1, 2001; 119(3): 681 - 683. [Full Text] [PDF]

				N. N. Bock, T. Rogers, J. R. Tapia, G. D. Herron, B. DeVoe, and L. J. Geiter Acceptability of Short-Course Rifampin and Pyrazinamide Treatment of Latent Tuberculosis Infection Among Jail Inmates Chest, March 1, 2001; 119(3): 833 - 837. [Abstract] [Full Text] [PDF]

				Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): S221 - 247. [Full Text] [PDF]

				D. P. CHIN, K. DERIEMER, P. M. SMALL, A. P. de LEON, R. STEINHART, G. F. SCHECTER, C. L. DALEY, A. R. MOSS, E. A. PAZ, R. M. JASMER, et al. Differences in Contributing Factors to Tuberculosis Incidence in U.S.-born and Foreign-born Persons Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1797 - 1803. [Abstract] [Full Text] [PDF]